FDA
-
-
-
-
-
-
-
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
-
-
-
-
-
-
-
Cabaletta Bio (CABA) Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
-
-
-
-
-
-
-
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
-
-
-
-
-
-
-
Cabaletta Bio Announces $35 Million Offering
-
-
-
-
-
-
-
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
-
-
-
-
-
-
-
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
-
251,865 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All